Skip to main content
. Author manuscript; available in PMC: 2015 Dec 18.
Published in final edited form as: Haemophilia. 2011 Dec 21;18(2):276–283. doi: 10.1111/j.1365-2516.2011.02713.x

Table 5.

Comparisons of health care utilization and health care expenditures by type of payer, 2008.

Medicaid Employer-sponsored insurance (ESI) [6] P-value
Health care utilization
No. of people        1164          435   –
No. of people w an inhibitor (% of haemophilia A)            27 (7%)            30 (3%) <0.01
No. of people with admission (%)            95 (22%)          164 (14%) <0.01
 No. of admission w ≥1 admission(s)           2.2 (2.2)           1.4 (1.0) <0.01
No. of people with ED visit (%)          224 (51%)          379 (33%) <0.01
 No. of ED visits w ≥1 visit (s)           3.3 (4.5)           2.8 (6.4)   0.29
Health care expenditures (mean[median])
Ratio (Medicaid/ESI) [6]
All 142 987 [46 737] 155 136 [73 548]   0.9 [0.6§**]
Children 113 867 [31 067] 150 680 [72 374]   0.8 [0.4§**]
 Haemophilia A
  w/o an inhibitor   83 981 [23 697] 142 057 [73 659]   0.6**[0.3§**]
  w an inhibitor 509 778 [55 038] 831 866 [461 527]   0.6 [0.1§]
 Haemophilia B 125 522 [49 521]   92 546 [36 177]   1.4[1.4§]
Adult 194 549 [73 291] 159 310 [76 088]   1.2[1.0§]
 w/o an inhibitor
  w/o blood-borne viral infection 184 765 [62 785] 125 861 [43 968]   1.5†*[1.4§]
  w blood-borne viral infection 178 648 [101 446] 188 056 [116 207]   0.9[0.9§]
 w an inhibitor 355 552 [344 607] 577 640 [176 218]   0.6[2.0§]
*

and

**

represent a 5% and a 1% level of significance, respectively.

t-test.

Chi-squared test.

§

Wilcoxon–Mann–Whitney test.

To compare mean and median estimates, we used t-tests and Wilcoxon–Mann–Whitney test, respectively.